Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.47 |
| ▸ | PRPS1 | P60891 | 1/20 | 0.47 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL308328 | 0.81 | PTGS2 (0.48) | ARCSNK2A2CSNK2A1PTGS2EGLN3 | |
| SCHEMBL3037931 | 0.79 | PRPS1 (0.54) | ARPRPS1EGLN3ADORA2BPOLB | |
| SCHEMBL14291770 | 0.79 | PTGS2 (0.49) | CSNK2A2CSNK2A1PTGS2EGLN3ADORA2B | |
| SCHEMBL3038500 | 0.78 | CSNK2A2 (0.53) | PRPS1CSNK2A2CSNK2A1PTGS2EGLN3 | |
| SCHEMBL306565 | 0.78 | PTGS2 (0.48) | PRPS1CSNK2A2CSNK2A1PTGS2EGLN3 | |
| SCHEMBL3042764 | 0.78 | PTGS2 (0.48) | CSNK2A2CSNK2A1PTGS2EGLN3ADORA2B | |
| SCHEMBL27625202 | 0.77 | AR (0.51) | ARSMN1; SMN2POLBGAANPC1 | |
| SCHEMBL3031989 | 0.76 | SMN1; SMN2 (0.65) | ARSMN1; SMN2POLBNPC1LMNA | |
| SCHEMBL306478 | 0.75 | PTGS2 (0.46) | CSNK2A2CSNK2A1PTGS2EGLN3ADORA2B | |
| SCHEMBL306877 | 0.75 | STAT3 (0.47) | ARCSNK2A2CSNK2A1PTGS2EGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2042490-A2 | Benzimidazole derivatives as vanilloid receptor antagonists | AstraZeneca AB (SE) | 2009-04-01 | — | — | EP | claimed |
| EP-1626964-B1 | NEW BENZIMIDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-01-21 | — | — | EP | claimed |
| US-20060287377-A1 | New benzimidazole derivatives | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | US | claimed |
| CN-1784387-A | Novel benzimidazole derivatives | ASTRAZENECA AB (SE) | 2006-06-07 | — | — | CN | claimed |
| EP-1626964-A2 | NEW BENZIMIDAZOLE DERIVATIVES | AstraZeneca AB (SE) | 2006-02-22 | — | — | EP | claimed |
| WO-2004100865-A2 | NEW BENZIMIDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-11-25 | — | — | WO | claimed |
| US-7645784-B2 | Benzimidazole derivatives | ASTRAZENECA AB (SE) | 2010-01-12 | — | — | US | disclosed |
| US-7645784-B2 | Benzimidazole derivatives | ASTRAZENECA AB (SE) | 2010-01-12 | — | — | US | disclosed |
| US-7645784-B2 | Benzimidazole derivatives | ASTRAZENECA AB (SE) | 2010-01-12 | — | — | US | disclosed |
| EP-2042490-A2 | Benzimidazole derivatives as vanilloid receptor antagonists | AstraZeneca AB (SE) | 2009-04-01 | — | — | EP | disclosed |
| EP-2042490-A2 | Benzimidazole derivatives as vanilloid receptor antagonists | AstraZeneca AB (SE) | 2009-04-01 | — | — | EP | disclosed |
| EP-1626964-B1 | NEW BENZIMIDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-01-21 | — | — | EP | disclosed |
| EP-1626964-B1 | NEW BENZIMIDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-01-21 | — | — | EP | disclosed |
| US-20060287377-A1 | New benzimidazole derivatives | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | US | disclosed |
| CN-1784387-A | Novel benzimidazole derivatives | ASTRAZENECA AB (SE) | 2006-06-07 | — | — | CN | disclosed |
| EP-1626964-A2 | NEW BENZIMIDAZOLE DERIVATIVES | AstraZeneca AB (SE) | 2006-02-22 | — | — | EP | disclosed |
| WO-2004100865-A2 | NEW BENZIMIDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287377-A1 | New benzimidazole derivatives | CYP2C9, CDK9, CCNI | AR 1166/4885PRPS1 484/4885CSNK2A2 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.